Bank of Montreal
BTAI icon

Bank of Montreal’s BioXcel Therapeutics BTAI Stock Holding History

Bank of Montreal’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-444
Closed -$9.51K – 3880
2024
Q2 		$9.51K Sell
444
-675
-60% -$22.6K ﹤0.01% 3662
2024
Q1 		$51K Sell
1,119
-1,675
-60% -$79.9K ﹤0.01% 3447
2023
Q4 		$142K Buy
2,794
+119
+4% +$6.62K ﹤0.01% 3273
2023
Q3 		$146K Buy
+2,675
New +$270K ﹤0.01% 3177

Other funds holding BTAI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of Montreal's BTAI Position: Q3 2024 in Review

Bank of Montreal sold out of BioXcel Therapeutics (BTAI) in Q3 2024, closing a stake of 1,957 shares — an estimated $42K sold.

Bank of Montreal first reported a position in BTAI in Q2 2018 and held it in 15 quarters. The position peaked at $146K in Q3 2023. 49 funds tracked by Wall St. Rank hold BTAI as of Q3 2024.

  • Bank of Montreal reported no remaining BioXcel Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Bank of Montreal sold 1,957 BioXcel Therapeutics shares in Q3 2024, an estimated $42K.
  • Bank of Montreal first reported a position in BioXcel Therapeutics in Q2 2018 and held it in 15 quarters.
  • Bank of Montreal's BioXcel Therapeutics position peaked at $146K in Q3 2023.
  • 49 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q3 2024.

Based on Bank of Montreal's 13F filing for Q3 2024, filed 13 Nov 2024.